title: Fluoroquinolones in the management of community-acquired pneumonia.
abstract: OBJECTIVE
  Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP).
  
  
  METHODS
  Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines.
  
  
  RESULTS
  Randomised clinical trials of respiratory fluoroquinolones (moxifloxacin, levofloxacin and gemifloxacin) in the treatment of CAP were identified and analysed. The bacteriology of CAP, and susceptibility rates, resistance rates and pharmacokinetic and pharmacodynamic properties of fluoroquinolones against causative pathogens in CAP, and adverse event profiles of these agents were described. Respiratory fluoroquinolones have broad-spectrum antibacterial activities against common causative pathogens in CAP and provide an important treatment option as monotherapy for outpatients with comorbidities and inpatients who are not admitted to the intensive care unit (ICU), including those with risk factors of drug-resistant Streptococcus pneumoniae. For treatment of ICU patients with severe CAP, it is recommended that fluoroquinolones be used in combination with a beta-lactam. Recent studies also demonstrated a more rapid resolution of clinical symptoms with the use of highly potent respiratory fluoroquinolones.
  
  
  CONCLUSIONS
  Appropriate use of fluoroquinolone agents may shorten the duration of antimicrobial therapy and the length of hospital stay and contribute to the decreased development of resistance in patients with CAP. Adverse event profiles of these agents should be considered to facilitate the selection of an appropriate fluoroquinolone for appropriate CAP patients.
  
  
  CONCLUSIONS
  The fluoroquinolone class, specifically those with adequate activity against respiratory pathogens, represents an important and convenient treatment option for patients with CAP.
authors.affiliation: Department of Internal Medicine, UC Davis School of Medicine, Davis, CA, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Albertson
authors.forename: N C
authors.initials: NC
authors.lastname: Dean
authors.forename: A A
authors.initials: AA
authors.lastname: El Solh
authors.forename: M H
authors.initials: MH
authors.lastname: Gotfried
authors.forename: C
authors.initials: C
authors.lastname: Kaplan
authors.forename: M S
authors.initials: MS
authors.lastname: Niederman
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000378:metabolism; D024841:Fluoroquinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000378:metabolism; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones